Filing Flows

Filing Flows › Companies › Bolt Biotherapeutics › Cash flow

Bolt Biotherapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.5M in Q2 2026 · −$31.5M over twelve months

Operating cash flow−$6.5M
Free cash flow−$6.5M

Analysis

In Q2 2026, Bolt Biotherapeutics generated −$6.5M of operating cash flow. That is $3.1M more than in Q2 2025 (−$9.6M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$31.5M; the largest uses were operating cash flow ($31.5M), capital spending ($85K); besides operations, cash came from other investing ($34.0M), asset & business sales ($717K); the cash balance rose by $3.2M.

Operating cash flow was −$6.5M against net income of −$7.7M. The largest differences: impairments +$808K, stock-based pay +$552K, gains on disposals −$373K.

Free cash flow

Bolt Biotherapeutics: free cash flow by quarterBolt Biotherapeutics: free cash flow by quarter−$14.0MQ3 2024−$14.4MQ4 2024−$13.4MQ1 2025−$9.6MQ2 2025−$9.8MQ3 2025−$7.2MQ4 2025−$8.0MQ1 2026−$6.5MQ2 2026
Operating cash flow less capital spending.
Bolt Biotherapeutics: operating cash flow against capital spendingBolt Biotherapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$14.0M$41KQ3 2024−$14.4M$0Q4 2024−$13.4M$0Q1 2025−$9.6M$0Q2 2025−$9.7M$72KQ3 2025−$7.2M$0Q4 2025−$8.0M$0Q1 2026−$6.5M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$6.5M, Capital spending $0.

Capital allocation, year by year

Bolt Biotherapeutics: where the cash came from (up) and went (down), by fiscal yearBolt Biotherapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$57.1MFY2021: Shares issued $53.2MFY2021: Capital spending −$2.3M$53.2MFY2021FY2022: Operating cash flow −$76.5MFY2022: Shares issued $503KFY2022: Capital spending −$2.0M$503KFY2022FY2023: Operating cash flow −$69.5MFY2023: Shares issued $253KFY2023: Capital spending −$206K$253KFY2023FY2024: Operating cash flow −$61.3MFY2024: Shares issued $108KFY2024: Asset sales $148KFY2024: Capital spending −$41K$256KFY2024FY2025: Operating cash flow −$39.9MFY2025: Shares issued $19KFY2025: Asset sales $963KFY2025: Capital spending −$72K$982KFY2025
Over these 5 years operating cash flow totalled −$304M; the largest uses were operating cash flow ($304M) and capital spending ($4.6M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$17.6M
Debtnone
Net cash$17.6M
Cash runway7 months

Bolt Biotherapeutics is burning cash: its operations consume cash, a free cash flow of −$31.5M a year at the current rate against $17.6M of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

Bolt Biotherapeutics: sources (+) and uses (−) of cash, Q2 2026Bolt Biotherapeutics: sources (+) and uses (−) of cash, Q2 2026Other investing$7.1MOperating cash flow−$6.5MCash drawn (+) / kept (−)−$1.3MAsset & business sales$686KShares issued$19K
Bolt Biotherapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Bolt Biotherapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$34.0MOperating cash flow−$31.5MCash drawn (+) / kept (−)−$3.2MAsset & business sales$717KCapital spending−$85KShares issued$30K

From profit to cash

Bolt Biotherapeutics: net income to operating cash flow, Q2 2026Bolt Biotherapeutics: net income to operating cash flow, Q2 2026Net income−$7.7MDepreciation & amortization$171KStock-based pay$552KImpairments$808KGains on disposals−$373KPayables$200KDeferred revenue$9KPrepaid and other assets−$81KOther liabilities−$26KOperating cash flow−$6.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$6.5M—$19K−$1.3M−$6.5M
Q1 2026−$8.0M—$6K$94K−$8.0M
Q4 2025−$7.2M—$5K$6.1M−$7.2M
Q3 2025−$9.7M−$72K—−$8.2M−$9.8M
Q2 2025−$9.6M—$14K−$1.2M−$9.6M
Q1 2025−$13.4M——−$1.2M−$13.4M
Q4 2024−$14.4M—$29K$2.2M−$14.4M
Q3 2024−$14.0M−$41K—−$3.2M−$14.0M

Bolt Biotherapeutics: income statement and cash flow

Bolt Biotherapeutics, Q2 2026: revenue $5K (-100% year over year). The chart follows the revenue to costs, profit and cash.

Bolt Biotherapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.